Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05733598 · ClinicalTrials.gov registry record · Phase 2
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
A Phase 2 study of Hepatocellular Carcinoma and Biliary Tract Cancer, sponsored by Replimune.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 11
- Study locations
NCT05733598 is a Phase 2 study of Hepatocellular Carcinoma and Biliary Tract Cancer that is actively recruiting participants, run by Replimune. The registered enrollment target is 60 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (77% lower). The trial reports 11 study locations across 6 states.
The verdict
NCT05733598, a Phase 2 study of Hepatocellular Carcinoma and Biliary Tract Cancer, is actively recruiting participants, sponsored by Replimune.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to assess the efficacy and safety of RP2 in combination with atezolizumab plus bevacizumab (Cohorts 1a and 1b) and RP2 monotherapy (Cohort 2) in the as second line treatment in patients with locally advanced unresectable, recurrent, and/or metastatic HCC and in combination with durvalumab as treatment in patients with unresectable locally advanced or metastatic BTC.
Conditions Studied
Interventions
- BIOLOGICAL Atezolizumab
- BIOLOGICAL Durvalumab
- BIOLOGICAL Bevacizumab
- BIOLOGICAL RP2
- BIOLOGICAL RP2 Monotherapy
Study Locations (11)
California
- Beverly Hills Cancer Center - Beverly Hills
- UC San Diego Moores Cancer Center - La Jolla
Florida
- Sylvester Comprehensive Cancer Center (University of Miami Hospital and Clinics) - Miami
- Moffitt Cancer Center - Tampa
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
- Montefiore Medical CenterMontefiore Medical Park - The Bronx
Pennsylvania
- University of Pennsylvania, Abramson Cancer Center - Philadelphia
- UPMC Hillman Cancer Center - Pittsburgh
Tennessee
- The West Clinic - Germantown
- University of Tennessee Medical Center - Knoxville
Maryland
- University of Maryland Medical Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-08-01 |
| Est. Completion | 2028-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05733598
The ClinicalTrials.gov registry entry for NCT05733598 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (77% lower). The listed sponsor is Replimune, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Atezolizumab is the first listed.
NCT05733598 reports 11 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT05733598 about?
NCT05733598 is a clinical study titled "Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC". The purpose of this study is to assess the efficacy and safety of RP2 in combination with atezolizumab plus bevacizumab (Cohorts 1a and 1b) and RP2 monotherapy (Cohort 2) in the as second line treatment in patients with locally advanced unresectable, recurrent, and/or metastatic HCC and in combinati...
What is the current status of trial NCT05733598?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2024-08-01. Estimated completion is 2028-07-01.
What conditions does trial NCT05733598 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Biliary Tract Cancer.
What interventions are being tested in trial NCT05733598?
The interventions under investigation include: Atezolizumab (BIOLOGICAL), Durvalumab (BIOLOGICAL), Bevacizumab (BIOLOGICAL), RP2 (BIOLOGICAL), RP2 Monotherapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT05733598?
This trial is sponsored by Replimune, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05733598 being conducted?
This trial has 11 study locations across California, Florida, Maryland, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
RECRUITING · Phase 2
-
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
-
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.